Third-Generation Hydroxyethyl Starch Causes Dose-Dependent Coagulopathy in Patients Undergoing Off-Pump Coronary Artery Bypass with Continuation of Preoperative Aspirin
DOI:
https://doi.org/10.1532/hsf.4061Keywords:
off-pump coronary artery bypass, hydroxyethyl starch, thromboelastometryAbstract
Background: We aimed to evaluate the effect of third-generation hydroxyethyl starch (6% HES 130/0.4) on hemostasis and perioperative blood loss in patients undergoing off-pump coronary artery bypass (OPCAB) with continuation of preoperative aspirin.
Methods: Forty-nine consecutive patients, who underwent OPCAB at a single institution between November 1, 2014 and March 31, 2016, were included. Coagulation tests, including thromboelastometry and clinical data of all patients, retrospectively were collected from anesthesia and medical records.
Results: The total amount of intraoperative crystalloid and HES was 2057.5 ± 771.6 mL (N = 32) and 1090.6 ± 645.0 mL (N = 32), respectively. In the coagulation pathway, the change ratio of fibrinogen concentration, prothrombin time, and fibrinogen thromboelastometry-maximum clot firmness (FIBTEM-MCF) significantly correlated with HES (P < 0.001, P = 0.00131, and P < 0.001, respectively), but not with crystalloid. In the coagulation pathway concerning interaction with platelets, the change ratio of platelet count, extrinsic thromboelastometry-clotting formation time (EXTEM-CFT), and EXTEM-MCF significantly were correlated with HES (P < 0.001, P < 0.001, and P < 0.001, respectively), but not with crystalloid. At chest closure, the hematocrit decreased in a dose-dependent manner with HES (P < 0.001), but not with crystalloid administration. There was an association between the change ratio of hematocrit and EXTEM-MCF (P = 0.00122). However, intra-postoperative blood loss was not correlated with HES 130/0.4 or crystalloid administration.
Conclusion: We found that 6% HES 130/0.4 prolonged coagulation testing in a dose-dependent manner due to hemodilution but did not increase blood loss in patients undergoing OPCAB with continuation of preoperative aspirin.
References
Aboul-Hassan SS, Stankowski T, Marczak J, et al. 2017. The use of preoperative aspirin in cardiac surgery: A systematic review and meta-analysis. J Card Surg. 32:758-74.
Ahn HJ, Kim JA, Lee AR, et al. 2016. The Risk of Acute Kidney Injury from Fluid Restriction and Hydroxyethyl Starch in Thoracic Surgery. Anesth Analg. 122:186-93.
Chassot PG, van der Linden P, Zaugg M, Mueller XM, Spahn DR. 2004. Off-pump coronary artery bypass surgery: physiology and anaesthetic management. Br J Anaesth. 92:400-13.
Gallandat Huet RC, Siemons AW, Baus D, et al. 2000. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth. 47:1207-15.
Gillies MA, Habicher M, Jhanji S, et al. 2014. Incidence of postoperative death and acute kidney injury associated with i.v. 6% hydroxyethyl starch use: systematic review and meta-analysis. Br J Anaesth. 112:25-34.
Holte K, Kehlet H. 2006. Fluid therapy and surgical outcomes in elective surgery: a need for reassessment in fast-track surgery. J Am Coll Surg. 202:971-89.
Jin S, Yu G, Hou R, Shen B, Jiang H. 2017. Effect of Hemodilution In Vitro with Hydroxyethyl Starch on Hemostasis. Med Sci Monit. 23:2189-97.
Kanda Y. 2013. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 48:452-8.
Kasper SM, Meinert P, Kampe S, et al. 2003. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology. 99:42-7.
Kind SL, Spahn-Nett GH, Emmert MY, et al. 2013. Is dilutional coagulopathy induced by different colloids reversible by replacement of fibrinogen and factor XIII concentrates? Anesth Analg. 117:1063-71.
Kozek-Langenecker SA. 2005. Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiology. 103:654-60.
Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. 2013. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 30:270-382.
Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. 2008. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg. 107:382-90.
Lee JS, Ahn SW, Song JW, et al. 2011. Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery. Circ J. 75:2397-402.
Liu FC, Liao CH, Chang YW, Liou JT, Day YJ. 2009. Hydroxyethyl starch interferes with human blood ex vivo coagulation, platelet function and sedimentation. Acta Anaesthesiol Taiwan. 47:71-8.
Min JJ, Cho HS, Jeon S, et al. 2017. Effects of 6% hydroxyethyl starch 130/0.4 on postoperative blood loss and kidney injury in off-pump coronary arterial bypass grafting: A retrospective study. Medicine (Baltimore). 96:e6801.
Navickis RJ, Haynes GR, Wilkes MM. 2012. Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a meta-analysis of randomized trials. J Thorac Cardiovasc Surg. 144:223-30.
Rasmussen KC, Johansson PI, Hojskov M, et al. 2014. Hydroxyethyl starch reduces coagulation competence and increases blood loss during major surgery: results from a randomized controlled trial. Ann Surg. 259:249-54.
Rasmussen KC, Secher NH, Pedersen T. 2016. Effect of perioperative crystalloid or colloid fluid therapy on hemorrhage, coagulation competence, and outcome: A systematic review and stratified meta-analysis. Medicine (Baltimore). 95:e4498.
Reuteler A, Axiak-Flammer S, Howard J, Adamik KN. 2017. Comparison of the effects of a balanced crystalloid-based and a saline-based tetrastarch solution on canine whole blood coagulation and platelet function. J Vet Emerg Crit Care (San Antonio). 27:23-34.
Schlimp CJ, Cadamuro J, Solomon C, Redl H, Schochl H. 2013. The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro. Blood Transfus. 11:510-7.
Schober P, Boer C, Schwarte LA. 2018. Correlation coefficients: appropriate use and interpretation. Anesth Analg 126:1763-8.
Schramko A, Suojaranta-Ylinen R, Kuitunen A, et al. 2010. Hydroxyethylstarch and gelatin solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Br J Anaesth. 104:691-7.
Schramko A, Suojaranta-Ylinen R, Niemi T, et al. 2015. The use of balanced HES 130/0.42 during complex cardiac surgery; effect on blood coagulation and fluid balance: a randomized controlled trial. Perfusion. 30:224-32.
Skhirtladze K, Base EM, Lassnigg A, et al. 2014. Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer's lactate on blood loss and coagulation after cardiac surgery. Br J Anaesth. 112:255-64.
Wilkes MM, Navickis RJ, Sibbald WJ. 2001. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg 72:527-33. discussion 534.
Windecker S, Kolh P, Alfonso F, et al. 2014. ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 35:2541-619.
